132 related articles for article (PubMed ID: 32653217)
21. Cutaneous adult xanthogranuloma with a small portion of BRAF
Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
[TBL] [Abstract][Full Text] [Related]
22. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
23. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
24. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
25.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
26. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
27. Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib.
Konstantinou MP; Lucas P; Uthurriague C; Severino-Freire M; Spenatto N; Gaudin C; Lamant L; Tournier E; Bulai-Livideanu C; Meyer N; Paul C
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e120-e121. PubMed ID: 32757402
[No Abstract] [Full Text] [Related]
28. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Langerhans Cell Histiocytosis with BRAF Mutation Affecting Sacral Vertebra: A Case Report and Disease Review.
Champaneri H; Banerjee AD
Pediatr Neurosurg; 2020; 55(3):169-174. PubMed ID: 32739910
[TBL] [Abstract][Full Text] [Related]
30. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
32. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
Aricò M
Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
[TBL] [Abstract][Full Text] [Related]
33. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
34. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
35. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.
Haroche J; Cohen-Aubart F; Emile JF; Donadieu J; Amoura Z
J Am Acad Dermatol; 2015 Jul; 73(1):e29-30. PubMed ID: 26089069
[No Abstract] [Full Text] [Related]
37. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
[TBL] [Abstract][Full Text] [Related]
38. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
39. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]